Volume 20, Issue 2
February 2018
Cover image
Cover image
Taken from Figure 1 of the article “Glioblastoma in elderly patients: solid conclusions built on shifting sand?” by Wick et al. beginning on p. 174.
ISSN 1522-8517
EISSN 1523-5866
Issue navigation
Volume 20, Issue 2, February 2018
Editorials
The siren song of bevacizumab: swan song or clarion call?
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 147–148, https://doi.org/10.1093/neuonc/nox244
Pediatric low-grade gliomas: a brave new world
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 149–150, https://doi.org/10.1093/neuonc/nox221
Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 151–152, https://doi.org/10.1093/neuonc/nox240
Highlights from the Literature
Highlights from the Literature
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 153–155, https://doi.org/10.1093/neuonc/nox247
Meeting Update
Meeting Update—Society for Neuro-Oncology 2017 Annual Meeting
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 156–159, https://doi.org/10.1093/neuonc/nox239
Reviews
Pediatric low-grade gliomas: next biologically driven steps
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 160–173, https://doi.org/10.1093/neuonc/nox141
Glioblastoma in elderly patients: solid conclusions built on shifting sand?
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 174–183, https://doi.org/10.1093/neuonc/nox133
Is the blood–brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 184–191, https://doi.org/10.1093/neuonc/nox175
Basic and Translational Investigations
Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 192–202, https://doi.org/10.1093/neuonc/nox119
Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 203–214, https://doi.org/10.1093/neuonc/nox134
microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 215–224, https://doi.org/10.1093/neuonc/nox138
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 225–235, https://doi.org/10.1093/neuonc/nox139
Divergent evolution of temozolomide resistance in glioblastoma stem cells is reflected in extracellular vesicles and coupled with radiosensitization
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 236–248, https://doi.org/10.1093/neuonc/nox142
Clinical Investigations
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 249–258, https://doi.org/10.1093/neuonc/nox154
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 259–267, https://doi.org/10.1093/neuonc/nox151
Brain volume reduction after whole-brain radiotherapy: quantification and prognostic relevance
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 268–278, https://doi.org/10.1093/neuonc/nox150
Neuroimaging
Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 279–288, https://doi.org/10.1093/neuonc/nox153
Letter to the Editor
Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss
Neuro-Oncology, Volume 20, Issue 2, February 2018, Pages 289–291, https://doi.org/10.1093/neuonc/nox217
Society News
Forthcoming Meetings
Neuro-Oncology, Volume 20, Issue 2, February 2018, Page 292, https://doi.org/10.1093/neuonc/nox246
Corrigendum
Corrigendum
Neuro-Oncology, Volume 20, Issue 2, February 2018, Page 293, https://doi.org/10.1093/neuonc/nox226
